Nasdaq · Biotech stocks database
CTY — City Therapeutics Inc.
CTY (City Therapeutics Inc.) stock: $20.71, $1.04B market cap. Data from Fully Diluted's biotech stocks database.
Enterprise value
Not disclosed
Balance sheet
| Cash | Not disclosed |
|---|
| Debt | Not disclosed |
|---|
| Net cash | Not disclosed |
|---|
| Enterprise value | Not disclosed |
|---|
| Basic shares | Not disclosed |
|---|
| Fully diluted shares | Not disclosed |
|---|
| Fully diluted market cap | Not disclosed |
|---|
| Cash per share | Not disclosed |
|---|
Share structure
Cap table components pending verification.
Price history
Loading CTY daily closes…
Loading price history…
Asset data not yet available for this company.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.